Tetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, has been evaluated in clinical trials for the treatment of progressive supranuclear palsy (PSP). While primarily approved for Huntington's disease chorea, tetrabenazine has been investigated for various movement disorders due to its ability to modulate dopaminergic neurotransmission[@tetrabenazine2007].
The interest in tetrabenazine for PSP stems from the complex neurotransmitter abnormalities in this disorder. PSP involves degeneration of subcortical structures including the substantia nigra pars reticulata (SNr), globus pallidus interna (GPi), and the subthalamic nucleus, leading to excessive inhibition of thalamocortical pathways. By modulating monoamine neurotransmission, particularly dopamine, tetrabenazine may help normalize motor output in these circuits.
| Parameter |
Details |
| Phase |
Phase 2 |
| Status |
Completed |
| Drug |
Tetrabenazine (Xenazine®) |
| Dosage |
12.5-100 mg daily (titrated) |
| Administration |
Oral, divided doses |
| Patient Population |
Patients with PSP (Richardson syndrome and variants) |
| Duration |
8-12 weeks per trial |
| Design |
Open-label and randomized controlled trials |
The clinical evaluation of tetrabenazine in PSP proceeded through several phases:
Initial open-label studies evaluated safety, tolerability, and preliminary efficacy signals in small cohorts of PSP patients. These studies established the dosing paradigm and identified potential responders.
¶ Phase 2: Randomized Controlled Trials
Subsequent randomized, placebo-controlled trials evaluated efficacy using standardized movement disorder scales. Primary endpoints included changes in:
- PSP Rating Scale (PSPRS)
- Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale
- Unified Dyskinesia Rating Scale (UDysRS)
Tetrabenazine exerts its effects through multiple mechanisms related to monoamine neurotransmission[@vmat2_biology][@dopamine_neurobiology]:
The primary mechanism involves inhibition of vesicular monoamine transporter 2 (VMAT2):
-
Vesicular Transport Blockade
- Tetrabenazine binds to VMAT2 in presynaptic neurons
- Inhibits the packaging of dopamine, norepinephrine, and serotonin into synaptic vesicles
- Reduces the releasable pool of monoamines
-
Monoamine Depletion
- Depletes synaptic stores of dopamine, norepinephrine, and serotonin
- Results in decreased monoamine availability for release
- Effects are reversible upon drug discontinuation
-
Reversible Action
- Unlike irreversible monoamine depleters, tetrabenazine's effects are reversible
- Allows for flexible dosing adjustments
- Recovery of monoamine stores upon discontinuation
The dopaminergic effects are central to therapeutic action[hd_chorea]:
-
Dopamine Reduction
- Decreases synaptic dopamine levels
- Reduces postsynaptic dopamine receptor stimulation
- Normalizes excessive dopaminergic signaling in movement disorders
-
Receptor Occupancy
- Indirectly reduces dopamine receptor occupancy
- Modulates both D1 and D2 receptor signaling
- Alters downstream signaling cascades
-
Hyperkinetic Control
- Helps control abnormal involuntary movements
- Reduces choreiform movements
- Improves motor control
In PSP, the basal ganglia output is characterized by[psp_trial_outcomes]:
-
Excessive Inhibition
- GPi and SNr are overactive
- Thalamocortical pathways are excessively inhibited
- Results in bradykinesia and rigidity
-
Dopaminergic Contributions
- Dopamine depletion contributes to motor dysfunction
- Nigrostriatal degeneration similar to PD
- Additional non-dopaminergic deficits
-
Modulation Strategy
- Tetrabenazine may reduce excessive dopaminergic tone in specific pathways
- May help normalize basal ganglia output
- Effects may be more relevant for specific symptom domains
Observed clinical effects include[psp_trial_outcomes]:
-
Dyskinesia Management
- May reduce choreiform movements in selected patients
- Particularly relevant for patients with chorea or dyskinesias
- Variable response across patients
-
Gait Improvement
- Some benefit in certain gait parameters
- May improve postural stability in some patients
- Effects on falls variable
-
Variable Response
- Response varies by patient
- Different symptom domains respond differently
- Subtype-specific effects observed
-
Non-Motor Symptoms
- Potential effects on neuropsychiatric symptoms
- May improve sleep in some patients
- Mood effects observed
Trial populations included:
-
Richardson Syndrome Patients
- Classic PSP presentation
- Vertical gaze palsy, postural instability, parkinsonism
- Most common PSP variant
-
PSP Variants
- PSP-P (parkinsonism predominant)
- PSP-PAGF (pure akinesia with gait freezing)
- PSP-CBS (corticobasal syndrome features)
- PSP-PLS (primary lateral sclerosis features)
-
Inclusion Criteria
- Clinical diagnosis of probable PSP
- Age 40-85 years
- Disease duration typically 1-7 years
- Able to tolerate study procedures
-
Exclusion Criteria
- Significant depression (contraindication)
- Suicidal ideation
- Significant cardiac disease
- Concomitant dopamine-depleting medications
Primary and secondary endpoints included[psp_trial_outcomes]:
-
Primary Endpoints
- PSP Rating Scale (PSPRS) total score
- UPDRS motor subscale (Part III)
- Clinical Global Impression of Change
-
Secondary Endpoints
- UDysRS (Unified Dyskinesia Rating Scale)
- PDQ-39 (Quality of Life)
- Caregiver burden scales
- Neuropsychiatric Inventory (NPI)
-
Safety Assessments
- Adverse event monitoring
- Depression scales
- Vital signs
- ECG monitoring
Key findings from clinical trials[psp_trial_outcomes]:
-
Variable Response
- Mixed results across PSP subtypes
- Some patients showed meaningful improvement
- Others showed minimal or no response
-
Symptom Domain Effects
- Most benefit observed in specific symptom domains
- Gait and balance may improve in some patients
- Dyskinesia reduction in selected cases
-
Response Predictors
- Younger age at onset may predict better response
- Earlier disease stage may respond better
- Specific subtypes may benefit more
Tolerability and adverse effects[hd_chorea][@tetrabenazine2007]:
-
Common Adverse Effects
- Sedation and drowsiness
- Depression and mood changes
- Orthostatic hypotension
- Fatigue
-
Neurological Effects
- Parkinsonism worsening in some cases
- Akathisia
- Dizziness
-
Psychiatric Effects
- Depression (significant concern in PSP)
- Anxiety
- Suicidal ideation (rare but monitored)
-
Safety Concerns
- Requires careful monitoring for depression
- Contraindicated in patients with depression
- Regular psychiatric assessment required
Summary of clinical trial outcomes:
| Outcome |
Finding |
| Motor function |
Variable improvement in some patients |
| Dyskinesias |
Reduction in selected patients |
| Quality of life |
Mixed results |
| Safety |
Acceptable with monitoring |
| Overall |
Not sufficient for widespread use in PSP |
The tetrabenazine trials inform PSP management in several ways[vmata2_inhibitors_advances][deutetrabenazine][valbenazine]:
-
Hyperkinetic Elements
- Addresses hyperkinetic components of PSP
- May reduce involuntary movements
- Role in specific symptom management
-
Motor Circuit Modulation
- Validates monoamine modulation approach
- Demonstrates role of dopamine in PSP symptoms
- Informs future therapeutic strategies
-
Mechanistic Insights
- VMAT2 as valid therapeutic target
- Monoamine depletion approach validated in other disorders
- Provides framework for other agents
-
Drug Development
- Foundation for newer VMAT2 inhibitors
- Lessons on dosing and monitoring
- Safety profile established
-
Selected Patients
- May provide benefit in selected patients
- Requires careful patient selection
- Monitoring essential
-
Alternative Agents
- Deutetrabenazine as alternative
- Valbenazine as alternative
- Different safety profiles
| Agent |
Advantages |
Disadvantages |
| Tetrabenazine |
Established efficacy in HD chorea |
Depression risk, requires monitoring |
| Deutetrabenazine |
Improved tolerability, deuterated |
Similar monitoring needs |
| Valbenazine |
Once-daily dosing, better profile |
Limited PSP data |
Deutetrabenazine (Austedo®) represents an improved formulation[deutetrabenazine]:
-
Deuterium Chemistry
- Deuterium substitution slows metabolism
- More stable blood levels
- Reduced dosing frequency
-
Advantages
- Better tolerability profile
- Less sedation
- More predictable kinetics
-
Application to PSP
- Being studied in PSP
- May have better side effect profile
- Similar mechanism of action
Valbenazine (Ingrezza®) is another VMAT2 inhibitor valbenazine]:
-
Pro-drug Design
- Valbenazine is a pro-drug
- Converted to active metabolite
- Once-daily dosing
-
Clinical Profile
- FDA approved for TD
- Being evaluated in other hyperkinetic disorders
- Favorable safety profile
-
Potential in PSP
- May be evaluated in PSP trials
- Different side effect profile
- Convenient dosing
-
Combination Approaches
- VMAT2 inhibitors with other agents
- Combined with dopaminergic therapy
- Synergistic effects
-
Biomarker Development
- Target engagement markers
- Response predictors
- Personalized treatment
-
Subtype-Specific Trials
- PSP-P may respond better
- Targeted populations
- Enriched study designs
-
Patient Selection
- Identify likely responders
- Avoid depression risk
- Consider disease stage
-
Monitoring Protocols
- Regular depression screening
- Vital sign monitoring
- Efficacy assessment
-
Treatment Integration
- Part of comprehensive management
- Adjunct to other therapies
- Individualized approach
- Unknown, Tetrabenazine in Movement Disorders (2007)
- Unknown, VMAT2 biology and function (n.d.)
- Unknown, Dopamine neurobiology in parkinsonism (n.d.)
- Unknown, Tetrabenazine in PSP clinical outcomes (n.d.)
- Unknown, Tetrabenazine in Huntington's disease chorea (n.d.)
- Unknown, VMAT2 inhibitors: advances and applications (n.d.)
- Unknown, Deutetrabenazine in movement disorders (n.d.)
- Unknown, Valbenazine for hyperkinetic disorders (n.d.)